EMAIL US AT info@bcan.org
SUPPORT HOTLINE (888) 901-2226
Donate Now

Bladder Cancer News

Announcing BCAN 2018 Young Investigator Awards!

The Bladder Cancer Advocacy Network (BCAN) is pleased to announce two 2018 Young Investigator Awards (YIA), to support the development of outstanding early career research scientists and clinical cancer research investigators who have demonstrated a commitment to improving the understanding and treatment of bladder cancer. In addition, for the first time,

Read More

Research Announcement | Accelerating Innovation in Military Medicine (AIMM) Funding Opportunity for Fiscal Year 2017 (FY17)

Defense Health Program, US Army Medical Research and Materiel Command (USAMRMC) The FY17 AIMM Program Announcement and General Application Instructions for the following award mechanism are anticipated to be posted on Grants.gov in November 2017. This program supports highly creative and conceptually innovative high-risk research with the potential to accelerate critical

Read More

HealthWell Foundation® now offers some financial assistance to Medicare patients with bladder cancer.

Bladder and Urothelial Cancers Fund Opens at HealthWell Foundation The HealthWell Foundation®, an independent non-profit that provides a financial lifeline for inadequately insured Americans, has opened a new fund to provide copayment and premium assistance to eligible Medicare patients living with bladder or urothelial cancer. Through the fund, HealthWell will

Read More

Bladder Cancer: A Patient-Friendly Guide to Understanding Your Diagnosis and Treatment Options is now available

Following a bladder cancer diagnosis in 2007, David Pulver went for a second opinion to Dr. Mark Schoenberg, a renowned urologist and expert in the field of urology. Together and alongside other doctors and patients, they wrote a patient-friendly book for those diagnosed with this disease. Bladder Cancer: A Patient-Friendly Guide to Understanding Your

Read More

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma

The FDA has now approved Merck’s KEYTRUDA® (pembrolizumab) as a first-line treatment for patients who are cisplatin-ineligible diagnosed with locally advanced or metastatic urothelial carcinoma. Additionally, second-line treatment in patients who are platinum-ineligible and have disease progression during or following chemotherapy or within 12 months of neoadjuvant or adjuvant treatment

Read More

Positive data from Phase 3 US Blue Light Cystoscopy with Cysview® study presented at AUA 2017 Meeting

On Sunday, May 14th, at the American Urological Association (AUA) 2017 Meeting in Boston, MA, Photocure ASA announced the latest data from their Phase 3 study with Blue Light Flexible Cystoscopy (BLFC™) with Hexvix®/Cysview®. This study showed that in 21.5% of the patients undergoing surveillance cystoscopy, a bladder cancer recurrence

Read More